{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:20:21Z","timestamp":1787840421354,"version":"build-2784847793"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This case highlights the development of gliptin-induced pemphigus in a patient shortly after initiating gliptin therapy for diabetes. It is essential to differentiate drug-induced pemphigus from idiopathic cases, as they can be clinically and histopathologically indistinguishable. A detailed medical history, including medication use, is crucial to identifying drug-induced conditions. The time interval between initiating the suspected drug and the onset of skin manifestations can vary widely from case to case. Improvement of the lesions following drug cessation confirms the diagnosis of drug-induced pemphigus.<\/jats:p>","DOI":"10.4103\/aam.aam_162_25","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T12:01:03Z","timestamp":1755691263000},"page":"709-711","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Gliptin-induced Pemphigus"],"prefix":"10.4103","volume":"25","author":[{"given":"Avinash","family":"Jadhav","sequence":"first","affiliation":[{"name":"Department of Dermatology, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr D. Y. Patil Vidyapeeth, Pimpri, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Arora","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr D. Y. Patil Vidyapeeth, Pimpri, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini Dattatray","family":"Mundhe","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr D. Y. Patil Vidyapeeth, Pimpri, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"R1-20260504","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1365-4362.1995.tb04430.x","article-title":"Dexamethasone-cyclophosphamide pulse therapy for pemphigus","volume":"34","author":"Pasricha","year":"1995","journal-title":"Int J Dermatol"},{"key":"R2-20260504","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2183\/pjab.86.524","article-title":"Autoimmune and infectious skin diseases that target desmogleins","volume":"86","author":"Amagai","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"R3-20260504","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","article-title":"Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin","volume":"26","author":"Skandalis","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R4-20260504","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1111\/1346-8138.14076","article-title":"Pemphigus vulgaris developing after 6-month treatment with a dipeptidyl peptidase-4 inhibitor: A case report","volume":"45","author":"Okauchi","year":"2018","journal-title":"J Dermatol"},{"key":"R5-20260504","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jcpt.12397","article-title":"Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: A case report and analysis of cases reported in the European pharmacovigilance database","volume":"41","author":"Garc\u00eda","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"R6-20260504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/B978-0-12-385855-9.00003-5","article-title":"Dipeptidyl peptidase in autoimmune pathophysiology","volume":"53","author":"Ohnuma","year":"2011","journal-title":"Adv Clin Chem"},{"key":"R7-20260504","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00403-014-1522-2","article-title":"Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: A randomized controlled trial","volume":"307","author":"El-Darouti","year":"2015","journal-title":"Arch Dermatol Res"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_162_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:22:23Z","timestamp":1787836943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_162_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_162_25","relation":{},"ISSN":["1596-3519","0975-5764"],"issn-type":[{"value":"1596-3519","type":"print"},{"value":"0975-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"2025-05-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}